Correlative analysis
AML
MUTANT, AML
P53 IHC was performed on baseline BM samples from 11 patients, all of whom had WT expression pattern. Assessment of paired BM samples collected post C1 demonstrated acquisition of mutant p53 expression (confirmed at low level by NGS: CyTOF analysis of PB and BM samples from AML patients treated with Milademetan, LDAC ±Venetoclax therapy was performed to interrogate the alterations in proteomic landscape and potential resistance mechanisms (Supplementary Fig. 